News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
News
Drug Development
Astellas Release: Exploratory Analysis Of The Phase I/II CHRYSALIS Study Of Gilteritinib Demonstrates First Molecular Response To FLT3 Inhibitor In Acute Myeloid Leukemia
June 6, 2017
|
3 min read
Twitter
LinkedIn
Facebook
Email
Print
• Maryland Jobs
• Washington Jobs
View More Jobs
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase I
Phase II
Astellas Pharma US, Inc.
MORE ON THIS TOPIC
Rare diseases
FDA Signs Off on Neurogene’s ‘Best-Case Scenario’ Pivotal Study Design for Rett Syndrome
July 1, 2025
·
2 min read
·
Tristan Manalac
Obesity
Protagonist Enters Obesity Fray With Triple-G Pill, Eyeing 2026 Clinical Start
July 1, 2025
·
2 min read
·
Tristan Manalac
Lymphoma
Pfizer Ends Mid-Stage Trial for CD47 Blood Cancer Drug, Citing Recruitment Problems
July 1, 2025
·
2 min read
·
Tristan Manalac
Cancer
Amgen’s Antibody Improves Overall Survival in Phase III Gastric Cancer Test
June 30, 2025
·
2 min read
·
Dan Samorodnitsky
